%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Victorine A. Mensah, Aly Gueye, Magatte Ndiaye, Nick J. Edwards, Danny Wright, Nicholas A. Anagnostou, Massamba Syll, Amy Ndaw, Annie Abiola, Carly Bliss, Jules-François Gomis, Ines Petersen, Caroline Ogwang, Tandakha Dieye, Nicola K. Viebig, Alison M. Lawrie, Rachel Roberts, Alfredo Nicosia, Babacar Faye, Oumar Gaye, Odile Leroy, Egeruan B. Imoukhuede, Katie J. Ewer, Philip Bejon, Adrian V. S. Hill, Badara Cisse, MVVC group
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 15 0 R/Annots 16 0 R/Contents 17 0 R/TrimBox[0 0 612 792]>>
endobj
16 0 obj
[18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R]
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref001)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref003)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref004)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref005)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref006)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref011)>>
endobj
24 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref012)>>
endobj
25 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref011)>>
endobj
26 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref013)>>
endobj
27 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref015)>>
endobj
28 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref016)>>
endobj
29 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref014)>>
endobj
30 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref017)>>
endobj
31 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref018)>>
endobj
32 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref019)>>
endobj
17 0 obj
[33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R 47 0 R 48 0 R]
endobj
33 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 624.2298 m
199.9998 624.2298 l
199.9998 624.7298 l
575.9997 624.7298 l
f*
0.83 0.64 0.02 0 k
346.9606 536.9386 m
351.7228 536.9386 l
h
f*
356.8819 536.9386 m
361.6441 536.9386 l
h
f*
400.8189 523.8992 m
405.5811 523.8992 l
h
f*
407.8488 523.8992 m
412.611 523.8992 l
h
f*
511.5402 445.9465 m
516.3024 445.9465 l
h
f*
521.4614 445.9465 m
530.9858 445.9465 l
h
f*
320.7685 432.9071 m
330.2929 432.9071 l
h
f*
477.2409 419.9244 m
486.7654 419.9244 l
h
f*
426.5575 341.915 m
436.0819 341.915 l
h
f*
441.2976 341.915 m
450.7654 341.915 l
h
f*
306.9921 289.9276 m
316.5165 289.9276 l
h
f*
518.7402 211.9181 m
528.2646 211.9181 l
h
f*
530.5323 211.9181 m
540 211.9181 l
h
f*
407.7354 94.9039 m
417.2598 94.9039 l
h
f*
419.5276 94.9039 m
429.052 94.9039 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(observed:)Tj
4.5652 0 Td
(12)Tj
1.3129 0 Td
(of)Tj
1.0503 0 Td
(57)Tj
1.3129 0 Td
(ME-TRAP)Tj
4.7025 0 Td
(vaccinees)Tj
4.613 0 Td
(became)Tj
3.7417 0 Td
(PCR)Tj
2.3155 0 Td
(positive)Tj
3.5686 0 Td
(during)Tj
2.954 0 Td
(the)Tj
1.5993 0 Td
(intensive)Tj
4.1118 0 Td
(monitor-)Tj
-35.8477 -1.474 Td
(ing)Tj
1.5336 0 Td
(period)Tj
2.954 0 Td
(as)Tj
1.2652 0 Td
(compared)Tj
4.6249 0 Td
(to)Tj
1.0443 0 Td
(13)Tj
1.3189 0 Td
(of)Tj
1.0443 0 Td
(the)Tj
1.5934 0 Td
(58)Tj
1.3188 0 Td
(controls)Tj
3.6821 0 Td
(\(P)Tj
1.2114 0 Td
(=)Tj
0.7997 0 Td
(0.80\).)Tj
2.7511 0 Td
(This)Tj
2.0946 0 Td
(trial)Tj
1.8023 0 Td
(confirms)Tj
3.9625 0 Td
(that)Tj
1.8738 0 Td
(vaccine)Tj
-34.8749 -1.474 Td
(efficacy)Tj
3.5746 0 Td
(against)Tj
3.4075 0 Td
(malaria)Tj
3.4553 0 Td
(infection)Tj
3.8969 0 Td
(in)Tj
0.9787 0 Td
(adults)Tj
2.8585 0 Td
(may)Tj
2.0946 0 Td
(be)Tj
1.3189 0 Td
(rapidly)Tj
3.121 0 Td
(assessed)Tj
4.3982 0 Td
(using)Tj
2.578 0 Td
(this)Tj
1.7605 0 Td
(efficient)Tj
3.6224 0 Td
(and)Tj
-37.0651 -1.474 Td
(cost-effective)Tj
6.0571 0 Td
(clinical)Tj
3.1688 0 Td
(trial)Tj
1.8023 0 Td
(design.)Tj
3.4075 0 Td
(Further)Tj
3.4135 0 Td
(efficacy)Tj
3.5746 0 Td
(evaluation)Tj
4.7145 0 Td
(of)Tj
1.0503 0 Td
(this)Tj
1.7545 0 Td
(vectored)Tj
4.0162 0 Td
(candidate)Tj
4.4996 0 Td
(vac-)Tj
-37.4589 -1.474 Td
(cine)Tj
2.029 0 Td
(approach)Tj
4.3384 0 Td
(in)Tj
0.9847 0 Td
(other)Tj
2.4706 0 Td
(malaria)Tj
3.4553 0 Td
(transmission)Tj
5.7707 0 Td
(settings)Tj
3.6283 0 Td
(and)Tj
1.8679 0 Td
(age-de-escala)Tj
6.2601 0 Td
(tion)Tj
1.8082 0 Td
(into)Tj
1.8082 0 Td
(the)Tj
1.5933 0 Td
(main)Tj
-36.0147 -1.474 Td
(target)Tj
2.751 0 Td
(age)Tj
1.8619 0 Td
(groups)Tj
3.2465 0 Td
(for)Tj
1.3725 0 Td
(a)Tj
0.7698 0 Td
(malaria)Tj
3.4553 0 Td
(vaccine)Tj
3.5687 0 Td
(is)Tj
0.9309 0 Td
(in)Tj
0.9847 0 Td
(progress.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 568.0062 cm
BT
/F3 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 550.9984 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Malaria)Tj
3.2995 0 Td
(transmission)Tj
5.3631 0 Td
(has)Tj
1.542 0 Td
(been)Tj
2.1203 0 Td
(on)Tj
1.2756 0 Td
(the)Tj
1.474 0 Td
(decline)Tj
3.0784 0 Td
(in)Tj
1.0375 0 Td
(many)Tj
2.4774 0 Td
(parts)Tj
2.1997 0 Td
(of)Tj
1.0148 0 Td
(Africa)Tj
2.6872 0 Td
(in)Tj
1.0375 0 Td
(association)Tj
4.6261 0 Td
(with)Tj
1.9956 0 Td
(scal-)Tj
-35.2287 -1.2982 Td
(ing)Tj
1.5023 0 Td
(up)Tj
1.2642 0 Td
(of)Tj
1.0148 0 Td
(effective)Tj
3.5093 0 Td
(control)Tj
3.1181 0 Td
(measures)Tj
3.9458 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(].)Tj
2.5909 0 Td
(Elimination)Tj
4.9946 0 Td
(and)Tj
1.7291 0 Td
(subsequent)Tj
4.7055 0 Td
(eradication)Tj
4.7225 0 Td
(of)Tj
1.0148 0 Td
(malaria)Tj
-34.1119 -1.3039 Td
(has)Tj
1.542 0 Td
(been)Tj
2.1203 0 Td
(the)Tj
1.4683 0 Td
(subject)Tj
3.0217 0 Td
(of)Tj
1.0148 0 Td
(discourse)Tj
3.9912 0 Td
(for)Tj
1.3833 0 Td
(several)Tj
2.9367 0 Td
(years)Tj
2.262 0 Td
([)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(].)Tj
2.3017 0 Td
(However,)Tj
4.0762 0 Td
(if)Tj
0.7767 0 Td
(the)Tj
1.4683 0 Td
(goal)Tj
1.8709 0 Td
(of)Tj
1.0148 0 Td
(eradication)Tj
4.7225 0 Td
(is)Tj
-35.9714 -1.2983 Td
(to)Tj
1.0261 0 Td
(be)Tj
1.1508 0 Td
(achieved,)Tj
3.9232 0 Td
(additional)Tj
4.2803 0 Td
(control)Tj
3.118 0 Td
(measures)Tj
3.9458 0 Td
(including)Tj
4.0422 0 Td
(effective)Tj
3.5093 0 Td
(and)Tj
1.7291 0 Td
(durable)Tj
3.2598 0 Td
(vaccines)Tj
3.5547 0 Td
(will)Tj
1.6611 0 Td
(be)Tj
-35.2004 -1.2983 Td
(required.)Tj
1.1962 -1.3039 Td
(The)Tj
1.7858 0 Td
(pre-erythocytic)Tj
6.3325 0 Td
(malaria)Tj
3.2258 0 Td
(vaccine)Tj
3.1918 0 Td
(RTS,)Tj
2.1544 0 Td
(S)Tj
0.6973 0 Td
(targeting)Tj
3.7927 0 Td
(the)Tj
1.4683 0 Td
(circumsporozoite)Tj
7.2283 0 Td
(protein,)Tj
3.3732 0 Td
(is)Tj
0.8504 0 Td
(the)Tj
-35.2967 -1.2982 Td
(most)Tj
2.2053 0 Td
(advanced)Tj
3.9911 0 Td
(vaccine)Tj
3.1975 0 Td
(in)Tj
1.0375 0 Td
(clinical)Tj
3.0727 0 Td
(development.)Tj
5.6353 0 Td
(In)Tj
1.1111 0 Td
(the)Tj
1.4684 0 Td
(recently)Tj
3.4072 0 Td
(published)Tj
4.1272 0 Td
(Phase)Tj
2.5228 0 Td
(III)Tj
1.2416 0 Td
(clinical)Tj
-33.0177 -1.2983 Td
(trial)Tj
1.8368 0 Td
(in)Tj
1.0318 0 Td
(over)Tj
1.9786 0 Td
(15,000)Tj
2.8233 0 Td
(infants)Tj
2.965 0 Td
(and)Tj
1.7291 0 Td
(children)Tj
3.5603 0 Td
(in)Tj
1.0318 0 Td
(several)Tj
2.9367 0 Td
(African)Tj
3.2371 0 Td
(countries,)Tj
4.1726 0 Td
(the)Tj
1.4683 0 Td
(efficacy)Tj
3.2258 0 Td
(of)Tj
1.0148 0 Td
(RTS,)Tj
2.1487 0 Td
(S,)Tj
-35.1607 -1.2983 Td
(with)Tj
1.9955 0 Td
(AS01)Tj
2.3301 0 Td
(as)Tj
1.0148 0 Td
(adjuvant,)Tj
3.9288 0 Td
(in)Tj
1.0375 0 Td
(young)Tj
2.7212 0 Td
(children)Tj
3.5546 0 Td
(was)Tj
1.7008 0 Td
(about)Tj
2.4945 0 Td
(50%)Tj
1.9275 0 Td
(during)Tj
2.9254 0 Td
(the)Tj
1.474 0 Td
(first)Tj
1.8028 0 Td
(year)Tj
1.9049 0 Td
([)Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(],)Tj
3.067 0 Td
(but)Tj
-33.8794 -1.3039 Td
(lower)Tj
2.4491 0 Td
(at)Tj
0.9524 0 Td
(3436%)Tj
3.3959 0 Td
(over)Tj
1.9786 0 Td
(4)Tj
0.6973 0 Td
(years)Tj
2.262 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(].)Tj
2.0806 0 Td
(Efficacy)Tj
3.3676 0 Td
(declines)Tj
3.4412 0 Td
(with)Tj
1.9956 0 Td
(time)Tj
2.0296 0 Td
(and)Tj
1.7291 0 Td
(was)Tj
1.7008 0 Td
(much)Tj
2.5171 0 Td
(lower)Tj
2.4491 0 Td
(against)Tj
-33.046 -1.2983 Td
(severe)Tj
2.6758 0 Td
(malaria)Tj
3.2258 0 Td
(after)Tj
2.0353 0 Td
(3)Tj
0.6973 0 Td
(years)Tj
2.2621 0 Td
(of)Tj
1.0148 0 Td
(follow-up)Tj
4.0932 0 Td
(in)Tj
1.0374 0 Td
(younger)Tj
3.5206 0 Td
(infants)Tj
2.9651 0 Td
(\(1017%\)[)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(].)Tj
5.93 0 Td
(This)Tj
1.9899 0 Td
(partial)Tj
2.7893 0 Td
(efficacy)Tj
-34.2366 -1.2982 Td
(necessitates)Tj
4.8415 0 Td
(the)Tj
1.4683 0 Td
(development)Tj
5.4142 0 Td
(of)Tj
1.0148 0 Td
(other)Tj
2.347 0 Td
(candidate)Tj
4.1046 0 Td
(vaccines,)Tj
3.7814 0 Td
(which)Tj
2.6475 0 Td
(could)Tj
2.4548 0 Td
(be)Tj
1.1509 0 Td
(used)Tj
2.0579 0 Td
(alone)Tj
2.3811 0 Td
(or)Tj
1.0942 0 Td
(in)Tj
-34.7582 -1.3039 Td
(combination)Tj
5.3461 0 Td
(with)Tj
1.9955 0 Td
(RTS,)Tj
2.1544 0 Td
(S.)Tj
0.924 0 Td
(Studies)Tj
3.1011 0 Td
(in)Tj
1.0318 0 Td
(multiple)Tj
3.566 0 Td
(disease)Tj
3.0217 0 Td
(areas)Tj
2.2394 0 Td
(show)Tj
2.3017 0 Td
(that)Tj
1.7801 0 Td
(vectored)Tj
3.651 0 Td
(vaccines)Tj
3.5546 0 Td
(induce)Tj
-34.6674 -1.2983 Td
(more)Tj
2.3414 0 Td
(potent)Tj
2.8119 0 Td
(T)Tj
0.8334 0 Td
(cell)Tj
1.559 0 Td
(responses)Tj
4.0932 0 Td
(that)Tj
1.7745 0 Td
(can)Tj
1.6271 0 Td
(provide)Tj
3.2882 0 Td
(significant)Tj
4.388 0 Td
(efficacy.)Tj
3.4525 0 Td
(Heterologous)Tj
5.6239 0 Td
(prime-boost)Tj
-31.7931 -1.2983 Td
(immunisation)Tj
5.8846 0 Td
(with)Tj
1.9956 0 Td
(chimpanzee)Tj
5.0173 0 Td
(adenovirus)Tj
4.6431 0 Td
(63)Tj
1.1736 0 Td
(\(ChAd63\))Tj
4.2519 0 Td
(and)Tj
1.7291 0 Td
(modified)Tj
3.8495 0 Td
(vaccinia)Tj
3.4752 0 Td
(virus)Tj
2.1997 0 Td
(Ankara)Tj
-34.2196 -1.3039 Td
(\(MVA\))Tj
3.1691 0 Td
(vectored)Tj
3.651 0 Td
(vaccines)Tj
3.5546 0 Td
(is)Tj
0.8504 0 Td
(a)Tj
0.6519 0 Td
(vaccination)Tj
4.8246 0 Td
(strategy)Tj
3.3278 0 Td
(recently)Tj
3.4129 0 Td
(shown)Tj
2.846 0 Td
(to)Tj
1.0261 0 Td
(induce)Tj
2.9367 0 Td
(cell-mediated)Tj
-30.2511 -1.2982 Td
(responses)Tj
4.0932 0 Td
(against)Tj
3.0273 0 Td
(several)Tj
/F13 1 Tf
2.9367 0 Td
[()]TJ
/F7 1 Tf
(.)Tj
/F13 1 Tf
0.9921 0 Td
[()9()11()4()1()10()4()16()-9( )12(\n)]TJ
/F7 1 Tf
4.4731 0 Td
(malaria)Tj
3.2258 0 Td
(antigens)Tj
3.5716 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(15)Tj
0 g
(].)Tj
3.5433 0 Td
(ChAd63-MVA)Tj
6.1965 0 Td
(expressing)Tj
-32.0596 -1.2983 Td
(the)Tj
/F13 1 Tf
1.4683 0 Td
[()]TJ
/F7 1 Tf
(.)Tj
/F13 1 Tf
0.9921 0 Td
[()9()11()4()1()10()4()16()-9( )12(\n)]TJ
/F7 1 Tf
4.4787 0 Td
(pre-erythrocytic)Tj
6.7011 0 Td
(antigen)Tj
3.2088 0 Td
(ME-TRAP)Tj
4.507 0 Td
(\(multiple)Tj
3.9062 0 Td
(epitope)Tj
3.1747 0 Td
(string)Tj
2.5285 0 Td
(thrombospon-)Tj
-30.9654 -1.2983 Td
(din-related)Tj
4.6374 0 Td
(adhesion)Tj
3.8154 0 Td
(protein\))Tj
3.4923 0 Td
(is)Tj
0.8504 0 Td
(one)Tj
1.7007 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(most)Tj
2.2053 0 Td
(advanced)Tj
3.9912 0 Td
(malaria)Tj
3.2258 0 Td
(vaccine)Tj
3.1974 0 Td
(candidates,)Tj
4.6885 0 Td
(capable)Tj
-34.2876 -1.3039 Td
(of)Tj
1.0147 0 Td
(inducing)Tj
3.7928 0 Td
(sterile)Tj
2.6135 0 Td
(protection)Tj
4.3823 0 Td
(in)Tj
1.0318 0 Td
(21%)Tj
1.9333 0 Td
(of)Tj
1.0148 0 Td
(malaria)Tj
3.2258 0 Td
(na)Tj
/F14 1 Tf
[()]TJ
/F7 1 Tf
(ve)Tj
2.3357 0 Td
(adults)Tj
2.6135 0 Td
(following)Tj
3.9798 0 Td
(controlled)Tj
4.32 0 Td
(human)Tj
-32.258 -1.2983 Td
(malaria)Tj
3.2258 0 Td
(infection)Tj
3.7927 0 Td
(\(CHMI\)[)Tj
0.83 0.64 0.02 0 k
(16)Tj
0 g
(].)Tj
-5.8223 -1.2982 Td
(Recently)Tj
3.6623 0 Td
(in)Tj
1.0375 0 Td
(Sukuta,)Tj
3.2031 0 Td
(The)Tj
1.7858 0 Td
(Gambia)Tj
3.3959 0 Td
(and)Tj
1.7291 0 Td
(Kilifi,)Tj
2.4548 0 Td
(Kenya,)Tj
2.9764 0 Td
(two)Tj
1.7121 0 Td
(phase)Tj
2.4831 0 Td
(Ib)Tj
1.0658 0 Td
(dose-escalation)Tj
6.3326 0 Td
(clinical)Tj
3.0784 0 Td
(tri-)Tj
-36.1131 -1.3039 Td
(als)Tj
1.2585 0 Td
(were)Tj
2.126 0 Td
(undertaken)Tj
4.8189 0 Td
(to)Tj
1.0261 0 Td
(assess)Tj
2.5171 0 Td
(the)Tj
1.4741 0 Td
(safety)Tj
2.4774 0 Td
(and)Tj
1.7291 0 Td
(immunogenicity)Tj
6.8598 0 Td
(of)Tj
1.0148 0 Td
(this)Tj
1.6725 0 Td
(approach)Tj
3.9514 0 Td
(in)Tj
1.0375 0 Td
(46)Tj
1.1679 0 Td
(healthy)Tj
-33.1311 -1.2983 Td
(malaria-exposed)Tj
6.8031 0 Td
(adults)Tj
2.6135 0 Td
(as)Tj
1.0148 0 Td
(previously,)Tj
4.5751 0 Td
(immunogenicity)Tj
6.8598 0 Td
(had)Tj
1.7064 0 Td
(only)Tj
1.9786 0 Td
(been)Tj
2.1203 0 Td
(described)Tj
4.0535 0 Td
(in)Tj
1.0375 0 Td
(predomi-)Tj
-32.7626 -1.2983 Td
(nantly)Tj
2.7495 0 Td
(Caucasian,)Tj
4.5354 0 Td
(malaria-na)Tj
/F14 1 Tf
[()]TJ
/F7 1 Tf
(ve)Tj
5.6976 0 Td
(adults.)Tj
2.8403 0 Td
(These)Tj
2.5682 0 Td
(two)Tj
1.7065 0 Td
(studies)Tj
2.9877 0 Td
(showed)Tj
3.2484 0 Td
(encouraging)Tj
5.2044 0 Td
(results,)Tj
3.0331 0 Td
(with)Tj
-34.5711 -1.3039 Td
(both)Tj
2.0579 0 Td
(vaccines)Tj
3.5546 0 Td
(shown)Tj
2.8516 0 Td
(to)Tj
1.0262 0 Td
(be)Tj
1.1508 0 Td
(safe)Tj
1.7235 0 Td
(and)Tj
1.7291 0 Td
(well)Tj
1.8199 0 Td
(tolerated,)Tj
3.9741 0 Td
(with)Tj
2.0012 0 Td
(high-level)Tj
4.1499 0 Td
(T)Tj
0.8334 0 Td
(cell)Tj
1.5591 0 Td
(responses)Tj
4.0932 0 Td
(induced)Tj
-32.5245 -1.2983 Td
(\(median)Tj
/F15 1 Tf
0 Tc
3.5773 0 Td
(>)Tj
/F7 1 Tf
-0.004 Tc
0.9921 0 Td
(1300)Tj
2.1259 0 Td
(Spot)Tj
2.0183 0 Td
(Forming)Tj
3.7247 0 Td
(Cells/million)Tj
5.3915 0 Td
(Peripheral)Tj
4.3596 0 Td
(Blood)Tj
2.5909 0 Td
(Monuclear)Tj
4.5921 0 Td
(Cells)Tj
2.1599 0 Td
([)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(17)Tj
0 g
(].)Tj
3.2542 0 Td
(The)Tj
1.7801 0 Td
(T)Tj
-36.5666 -1.2982 Td
(cell)Tj
1.559 0 Td
(responses)Tj
4.0932 0 Td
(appeared)Tj
3.8664 0 Td
(to)Tj
1.0262 0 Td
(be)Tj
1.1508 0 Td
(the)Tj
1.4684 0 Td
(most)Tj
2.2053 0 Td
(potent)Tj
2.8176 0 Td
(reported)Tj
3.6567 0 Td
(in)Tj
1.0375 0 Td
(Africa)Tj
2.6872 0 Td
(for)Tj
1.389 0 Td
(any)Tj
1.6554 0 Td
(vaccine)Tj
3.1918 0 Td
(type)Tj
1.9162 0 Td
(and)Tj
1.7291 0 Td
(were)Tj
-35.4498 -1.3039 Td
(therefore)Tj
3.8437 0 Td
(consistent)Tj
4.2463 0 Td
(with)Tj
1.9899 0 Td
(the)Tj
1.4627 0 Td
(growing)Tj
3.5206 0 Td
(evidence)Tj
3.702 0 Td
(that)Tj
1.7688 0 Td
(ChAd63)Tj
3.566 0 Td
(and)Tj
1.7234 0 Td
(MVA)Tj
2.4831 0 Td
(were)Tj
2.1147 0 Td
(promising)Tj
4.337 0 Td
(vectors)Tj
-34.7582 -1.2983 Td
(for)Tj
1.3832 0 Td
(clinical)Tj
3.0785 0 Td
(use.)Tj
1.7574 0 Td
(In)Tj
1.1055 0 Td
(Kilifi)Tj
2.2337 0 Td
(in)Tj
1.0318 0 Td
(Eastern)Tj
3.2258 0 Td
(Kenya,)Tj
2.9821 0 Td
(malaria)Tj
3.2258 0 Td
(is)Tj
0.8503 0 Td
(endemic)Tj
3.651 0 Td
(with)Tj
1.9956 0 Td
(two)Tj
1.7121 0 Td
(transmission)Tj
5.3632 0 Td
(seasons)Tj
-33.596 -1.2983 Td
(\(April-June)Tj
4.8245 0 Td
(and)Tj
1.7291 0 Td
(October-December\))Tj
8.3168 0 Td
(while)Tj
2.3698 0 Td
(in)Tj
1.0374 0 Td
(Senegal)Tj
3.2372 0 Td
(the)Tj
1.4683 0 Td
(transmission)Tj
5.3631 0 Td
(is)Tj
0.8504 0 Td
(made)Tj
2.4208 0 Td
(of)Tj
1.0148 0 Td
(one)Tj
1.7008 0 Td
(short)Tj
-34.333 -1.2982 Td
(and)Tj
1.7291 0 Td
(intense)Tj
3.0897 0 Td
(transmission)Tj
5.3631 0 Td
(season)Tj
2.8573 0 Td
(\(July)Tj
2.1203 0 Td
(to)Tj
1.0205 0 Td
(August-November\).)Tj
8.2431 0 Td
(It)Tj
0.8617 0 Td
(was)Tj
1.7008 0 Td
(therefore)Tj
3.8494 0 Td
(useful)Tj
2.5966 0 Td
(to)Tj
1.0261 0 Td
(assess)Tj
-34.4577 -1.3039 Td
(the)Tj
1.4683 0 Td
(safety,)Tj
2.7042 0 Td
(immunogenicity)Tj
6.8598 0 Td
(and)Tj
1.7291 0 Td
(efficacy)Tj
3.2202 0 Td
(of)Tj
1.0148 0 Td
(candidate)Tj
4.1045 0 Td
(vaccine)Tj
3.1975 0 Td
(in)Tj
1.0375 0 Td
(semi-immune)Tj
5.845 0 Td
(West)Tj
2.2677 0 Td
(African)Tj
-33.4486 -1.2983 Td
(adults)Tj
2.6135 0 Td
(exposed)Tj
3.4469 0 Td
(to)Tj
1.0261 0 Td
(different)Tj
3.651 0 Td
(malaria)Tj
3.2315 0 Td
(transmission)Tj
5.3631 0 Td
(conditions.)Tj
-18.1359 -1.2983 Td
(The)Tj
1.7858 0 Td
(use)Tj
1.5307 0 Td
(of)Tj
1.0148 0 Td
(PCR)Tj
2.0636 0 Td
(detection)Tj
3.9401 0 Td
(has)Tj
1.5421 0 Td
(been)Tj
2.1203 0 Td
(found)Tj
2.6192 0 Td
(to)Tj
1.0261 0 Td
(be)Tj
1.1508 0 Td
(feasible)Tj
3.1692 0 Td
(and)Tj
1.7291 0 Td
(cost-effective)Tj
5.4538 0 Td
(in)Tj
1.0318 0 Td
(studies)Tj
2.9877 0 Td
(con-)Tj
-34.3613 -1.3039 Td
(ducted)Tj
2.948 0 Td
(in)Tj
1.0374 0 Td
(The)Tj
1.7802 0 Td
(Gambia)Tj
3.3959 0 Td
(and)Tj
1.7291 0 Td
(more)Tj
2.3414 0 Td
(recently)Tj
3.4129 0 Td
(in)Tj
1.0375 0 Td
(Kenya)Tj
2.7495 0 Td
([)Tj
0.83 0.64 0.02 0 k
(18)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(19)Tj
0 g
(].)Tj
3.2542 0 Td
(These)Tj
2.5682 0 Td
(clinical)Tj
3.0784 0 Td
(efficacy)Tj
3.2201 0 Td
(trials)Tj
2.1997 0 Td
(mea-)Tj
-34.7525 -1.2983 Td
(sure)Tj
1.9048 0 Td
(time)Tj
2.0239 0 Td
(to)Tj
1.0262 0 Td
(PCR-detected)Tj
5.7599 0 Td
(infection)Tj
3.7928 0 Td
(after)Tj
2.0352 0 Td
(drug)Tj
2.1147 0 Td
(clearance)Tj
3.9458 0 Td
(of)Tj
1.0148 0 Td
(parasites.)Tj
3.9118 0 Td
(Efficacy)Tj
3.3675 0 Td
(against)Tj
3.0274 0 Td
(infection)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 224.5039 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Safety,)Tj
3.2882 0 Td
(Immunog)Tj
4.1031 0 Td
(enicity)Tj
3.0048 0 Td
(and)Tj
1.8567 0 Td
(Efficacy)Tj
3.6638 0 Td
(of)Tj
1.0418 0 Td
(ChAd63-M)Tj
4.7055 0 Td
(VA-METR)Tj
4.4504 0 Td
(AP)Tj
1.5378 0 Td
(against)Tj
/F6 1 Tf
3.3875 0 Td
(P.)Tj
1.1551 0 Td
(falcipar)Tj
3.1536 0 Td
(um)Tj
/F0 1 Tf
1.5945 0 Td
(in)Tj
0.9779 0 Td
(African)Tj
3.2811 0 Td
(Adults)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.4748 0 Td
(DOI:10.137)Tj
5.0387 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.0167)Tj
3.5434 0 Td
(951)Tj
2.6362 0 Td
(December)Tj
4.7622 0 Td
(15,)Tj
1.5874 0 Td
(2016)Tj
36.7515 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(16)Tj
/F10 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(Developmen)Tj
4.6417 0 Td
(t)Tj
0.4748 0 Td
(Cooperation)Tj
4.7127 0 Td
(Agency)Tj
2.9551 0 Td
(\(Sida\))Tj
2.4449 0 Td
(and)Tj
1.5874 0 Td
(Irish)Tj
-16.8166 -1.3748 Td
(Aid.)Tj
1.637 0 Td
(The)Tj
1.5874 0 Td
(work)Tj
2.0622 0 Td
(was)Tj
1.7008 0 Td
(also)Tj
1.7292 0 Td
(supported)Tj
3.9968 0 Td
(by)Tj
1.1126 0 Td
(the)Tj
1.3678 0 Td
(Dakar)Tj
-15.1938 -1.3749 Td
(University)Tj
3.9189 0 Td
(Cheikh)Tj
2.7283 0 Td
(Anta)Tj
1.8922 0 Td
(Diop.)Tj
2.1685 0 Td
(The)Tj
1.5945 0 Td
(funders)Tj
3.0402 0 Td
(had)Tj
1.5874 0 Td
(no)Tj
-16.93 -1.3748 Td
(role)Tj
1.6157 0 Td
(in)Tj
0.8858 0 Td
(study)Tj
2.2678 0 Td
(design,)Tj
2.8984 0 Td
(data)Tj
1.793 0 Td
(collection)Tj
3.7346 0 Td
(and)Tj
1.5874 0 Td
(analysis,)Tj
-14.7827 -1.3748 Td
(decision)Tj
3.2882 0 Td
(to)Tj
0.9496 0 Td
(publish,)Tj
3.1465 0 Td
(or)Tj
0.9992 0 Td
(preparation)Tj
4.4433 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
-13.7764 -1.3748 Td
(manuscript.)Tj
4.6417 0 Td
(ReiThera)Tj
3.515 0 Td
(\(formerly)Tj
3.6638 0 Td
(Okairos)Tj
2.8205 0 Td
(\),)Tj
0.7512 0 Td
(provided)Tj
-15.3922 -1.3748 Td
(support)Tj
3.0968 0 Td
(in)Tj
0.8859 0 Td
(the)Tj
1.3748 0 Td
(form)Tj
2.0055 0 Td
(of)Tj
0.9496 0 Td
(salaries)Tj
3.0189 0 Td
(for)Tj
1.2615 0 Td
(author)Tj
2.622 0 Td
(AN,)Tj
1.5591 0 Td
(but)Tj
-16.7741 -1.3748 Td
(did)Tj
1.3606 0 Td
(not)Tj
1.4244 0 Td
(have)Tj
1.9559 0 Td
(any)Tj
1.5378 0 Td
(additiona)Tj
3.3733 0 Td
(l)Tj
0.4181 0 Td
(role)Tj
1.6158 0 Td
(in)Tj
0.8858 0 Td
(the)Tj
1.3677 0 Td
(study)Tj
2.2678 0 Td
(design,)Tj
-16.2072 -1.3748 Td
(data)Tj
1.7929 0 Td
(collection)Tj
3.7347 0 Td
(and)Tj
1.5945 0 Td
(analysis)Tj
2.9622 0 Td
(,)Tj
0.4464 0 Td
(decision)Tj
3.2883 0 Td
(to)Tj
0.9496 0 Td
(publish,)Tj
3.1465 0 Td
(or)Tj
-17.9151 -1.3748 Td
(preparation)Tj
4.4433 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(manuscript.)Tj
4.6347 0 Td
(The)Tj
1.5945 0 Td
(specific)Tj
3.0189 0 Td
(role)Tj
1.6158 0 Td
(of)Tj
-17.6245 -1.3749 Td
(this)Tj
1.5661 0 Td
(author)Tj
2.6221 0 Td
(is)Tj
0.8362 0 Td
(articulate)Tj
3.3591 0 Td
(d)Tj
0.6945 0 Td
(in)Tj
0.8858 0 Td
(the)Tj
1.3748 0 Td
(`author)Tj
-11.3386 -1.3748 Td
(contributio)Tj
3.9897 0 Td
(ns')Tj
1.3111 0 Td
(section.)Tj
/F9 1 Tf
-5.3008 -2.126 Td
(Competing)Tj
4.3795 0 Td
(Interests)Tj
3.3307 0 Td
(:)Tj
/F10 1 Tf
0.4819 0 Td
(We)Tj
1.4457 0 Td
(have)Tj
1.9559 0 Td
(the)Tj
1.3678 0 Td
(following)Tj
-12.9615 -1.3748 Td
(interests.)Tj
3.6142 0 Td
(Adrian)Tj
2.6149 0 Td
(V.S.)Tj
1.715 0 Td
(Hill)Tj
1.389 0 Td
(is)Tj
0.8362 0 Td
(a)Tj
0.6378 0 Td
(named)Tj
2.7638 0 Td
(inventor)Tj
3.2386 0 Td
(on)Tj
-16.8095 -1.3748 Td
(patent)Tj
2.5228 0 Td
(applicati)Tj
3.0402 0 Td
(ons)Tj
1.5945 0 Td
(and)Tj
1.5874 0 Td
(patents)Tj
2.941 0 Td
(on)Tj
1.1622 0 Td
(malaria)Tj
-12.8481 -1.3748 Td
(vectored)Tj
3.4157 0 Td
(vaccines)Tj
3.4158 0 Td
(and)Tj
1.5874 0 Td
(immunisatio)Tj
4.6063 0 Td
(n)Tj
0.6945 0 Td
(regimes)Tj
-13.7197 -1.3748 Td
(including)Tj
3.5858 0 Td
(the)Tj
1.3748 0 Td
(following)Tj
3.5859 0 Td
(\(WO2008/)Tj
3.848 0 Td
(122769,)Tj
-12.3945 -1.3748 Td
(Adenoviral)Tj
4.1244 0 Td
(vector)Tj
2.5228 0 Td
(encoding)Tj
3.6213 0 Td
(malaria)Tj
2.9268 0 Td
(antigen;)Tj
3.1607 0 Td
(and)Tj
-16.356 -1.3749 Td
(WO)Tj
1.6157 0 Td
(2008/122)Tj
3.5646 0 Td
(811)Tj
1.6441 0 Td
(Novel)Tj
2.3174 0 Td
(adenovirus)Tj
4.2945 0 Td
(vectors\).)Tj
-13.4363 -1.3748 Td
(Egeruan)Tj
3.2669 0 Td
(Imoukhue)Tj
3.7418 0 Td
(de)Tj
1.1126 0 Td
(and)Tj
1.5945 0 Td
(Ines)Tj
1.7858 0 Td
(Petersen)Tj
3.4725 0 Td
(were)Tj
-14.9741 -1.3748 Td
(employees)Tj
4.2236 0 Td
(of)Tj
0.9496 0 Td
(EVI)Tj
1.474 0 Td
(at)Tj
0.893 0 Td
(the)Tj
1.3677 0 Td
(time)Tj
1.8496 0 Td
(of)Tj
0.9425 0 Td
(the)Tj
1.3749 0 Td
(study,)Tj
2.4874 0 Td
(which)Tj
-15.5623 -1.3748 Td
(supports)Tj
3.522 0 Td
(the)Tj
1.3678 0 Td
(developm)Tj
3.6283 0 Td
(ent)Tj
1.3748 0 Td
(and)Tj
1.5875 0 Td
(testing)Tj
2.7141 0 Td
(of)Tj
0.9497 0 Td
(malaria)Tj
-15.1442 -1.3748 Td
(vaccines.)Tj
3.6425 0 Td
(Nicola)Tj
2.5087 0 Td
(Viebig)Tj
2.5016 0 Td
(is)Tj
0.8291 0 Td
(an)Tj
1.1197 0 Td
(employe)Tj
3.1536 0 Td
(e)Tj
0.6449 0 Td
(of)Tj
0.9496 0 Td
(EVI)Tj
1.474 0 Td
(and)Tj
-16.8237 -1.3748 Td
(Odile)Tj
2.0905 0 Td
(Leroy)Tj
2.3174 0 Td
(is)Tj
0.8291 0 Td
(executive)Tj
3.6709 0 Td
(director)Tj
3.0756 0 Td
(of)Tj
0.9496 0 Td
(EVI.)Tj
1.7008 0 Td
(Author)Tj
2.5016 0 Td
(s)Tj
-17.1355 -1.3819 Td
(from)Tj
2.0126 0 Td
(ReiThera)Tj
3.515 0 Td
(\(formerly)Tj
3.6638 0 Td
(Okairos)Tj
2.8205 0 Td
(\))Tj
0.5315 0 Td
(are)Tj
1.3677 0 Td
(employees)Tj
4.2236 0 Td
(of)Tj
-18.1347 -1.3748 Td
(and/or)Tj
2.622 0 Td
(shareholder)Tj
4.3867 0 Td
(s)Tj
0.6449 0 Td
(in)Tj
0.8858 0 Td
(ReiThera,)Tj
3.7417 0 Td
(which)Tj
2.4237 0 Td
(is)Tj
-14.7048 -1.3749 Td
(developing)Tj
4.2378 0 Td
(vectored)Tj
3.4158 0 Td
(vaccines)Tj
3.4157 0 Td
(for)Tj
1.2544 0 Td
(malaria)Tj
2.9339 0 Td
(and)Tj
1.5874 0 Td
(other)Tj
-16.845 -1.3748 Td
(diseases.)Tj
3.6425 0 Td
(Alfredo)Tj
2.863 0 Td
(Nicosia)Tj
2.9339 0 Td
(was)Tj
1.7008 0 Td
(employed)Tj
3.8551 0 Td
(by)Tj
-14.9953 -1.3748 Td
(ReiThera)Tj
3.522 0 Td
(\(former)Tj
2.8205 0 Td
(ly)Tj
0.8362 0 Td
(Okairos\))Tj
3.352 0 Td
(at)Tj
0.9 0 Td
(the)Tj
1.3678 0 Td
(time)Tj
1.8425 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
-15.5906 -1.3748 Td
(study.)Tj
2.4874 0 Td
(There)Tj
2.3173 0 Td
(are)Tj
1.3748 0 Td
(no)Tj
1.1622 0 Td
(further)Tj
2.7142 0 Td
(patents,)Tj
3.1678 0 Td
(products)Tj
3.5221 0 Td
(in)Tj
-16.7458 -1.3748 Td
(developm)Tj
3.6283 0 Td
(ent)Tj
1.3748 0 Td
(or)Tj
0.9993 0 Td
(marketed)Tj
3.6992 0 Td
(products)Tj
3.515 0 Td
(to)Tj
0.9496 0 Td
(declare.)Tj
3.104 0 Td
(This)Tj
-17.2702 -1.3748 Td
(does)Tj
2.0126 0 Td
(not)Tj
1.4173 0 Td
(alter)Tj
1.8213 0 Td
(our)Tj
1.474 0 Td
(adherence)Tj
4.0536 0 Td
(to)Tj
0.9496 0 Td
(all)Tj
1.0276 0 Td
(the)Tj
1.3677 0 Td
(PLOS)Tj
2.3315 0 Td
(ONE)Tj
-16.4552 -1.3748 Td
(policies)Tj
3.0118 0 Td
(on)Tj
1.1622 0 Td
(sharing)Tj
2.9835 0 Td
(data)Tj
1.7929 0 Td
(and)Tj
1.5874 0 Td
(materials,)Tj
3.8339 0 Td
(as)Tj
1.063 0 Td
(detailed)Tj
-15.4347 -1.3749 Td
(online)Tj
2.4449 0 Td
(in)Tj
0.8858 0 Td
(the)Tj
1.3748 0 Td
(guide)Tj
2.2536 0 Td
(for)Tj
ET
endstream
endobj
34 0 obj
<>stream
endstream
endobj
35 0 obj
<>stream
endstream
endobj
36 0 obj
<>stream
endstream
endobj
37 0 obj
<>stream
endstream
endobj
38 0 obj
<>stream
endstream
endobj
39 0 obj
<>stream
endstream
endobj
40 0 obj
<>stream
endstream
endobj
41 0 obj
<>stream
endstream
endobj
42 0 obj
<>stream
endstream
endobj
43 0 obj
<>stream
endstream
endobj
44 0 obj
<>stream
endstream
endobj
45 0 obj
<>stream
endstream
endobj
46 0 obj
<>stream
endstream
endobj
47 0 obj
<>stream
endstream
endobj
48 0 obj
<>stream
BT
8.2134 37.9632 Td
(authors.)Tj
ET
Q
endstream
endobj
49 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 15 0 R/Annots 51 0 R/Contents 52 0 R/TrimBox[0 0 612 792]>>
endobj
51 0 obj
[53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R]
endobj
53 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref019)>>
endobj
54 0 obj
<>/Border[0 0 0]/A 60 0 R>>
endobj
60 0 obj
<>
endobj
55 0 obj
<>/Border[0 0 0]/A 61 0 R>>
endobj
61 0 obj
<>
endobj
56 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref020)>>
endobj
57 0 obj
<>/Border[0 0 0]/A 62 0 R>>
endobj
62 0 obj
<>
endobj
58 0 obj
<>/Border[0 0 0]/A 63 0 R>>
endobj
63 0 obj
<>
endobj
59 0 obj
<>/Border[0 0 0]/Dest(Rpone.0167951.ref021)>>
endobj
52 0 obj
[64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R]
endobj
64 0 obj
<>stream
q
0.83 0.64 0.02 0 k
535.9748 680.315 m
545.3858 680.315 l
h
f*
543.685 582.6331 m
568.9701 582.6331 l
h
f*
200.0126 569.6504 m
258.9732 569.6504 l
258.9732 569.5937 l
200.0126 569.5937 l
f*
498.8409 471.9118 m
508.1953 471.9118 l
h
f*
275.4709 237.9402 m
362.948 237.9402 l
h
f*
200.0126 224.9008 m
290.1543 224.9008 l
h
f*
422.589 159.9307 m
432.1134 159.9307 l
h
f*
0 g
1 j
1 J
0 w
10 0 0 10 200.0125 707.4141 cm
BT
/F7 1 Tf
1 TL
-0.01 Tc
0 0 Td
(is)Tj
0.8333 0 Td
(measured)Tj
4.0592 0 Td
(over)Tj
1.9559 0 Td
(an)Tj
1.1906 0 Td
(8-week)Tj
3.0387 0 Td
(follow-up)Tj
4.0365 0 Td
(period)Tj
2.8006 0 Td
(starting)Tj
3.2145 0 Td
(14)Tj
1.1622 0 Td
(days)Tj
1.9729 0 Td
(after)Tj
2.0012 0 Td
(the)Tj
1.457 0 Td
(final)Tj
1.9729 0 Td
(vaccination)Tj
4.7565 0 Td
(\(7)Tj
1.0262 0 Td
(days)Tj
-35.4782 -1.3039 Td
(after)Tj
2.0012 0 Td
(drug)Tj
2.092 0 Td
(clearance\).)Tj
4.4446 0 Td
(In)Tj
1.0999 0 Td
(a)Tj
0.6463 0 Td
(Phase)Tj
2.4945 0 Td
(IIb)Tj
1.3889 0 Td
(trial)Tj
1.8085 0 Td
(of)Tj
1.0035 0 Td
(vaccine)Tj
3.1521 0 Td
(efficacy)Tj
3.1748 0 Td
(in)Tj
1.0261 0 Td
(120)Tj
1.6271 0 Td
(Kenyan)Tj
3.2655 0 Td
(adults,)Tj
2.8006 0 Td
(efficacy)Tj
-32.0256 -1.2982 Td
(against)Tj
2.9876 0 Td
(infection)Tj
3.7361 0 Td
(was)Tj
1.6781 0 Td
(67%)Tj
1.9105 0 Td
(\(95%CI)Tj
3.2372 0 Td
(33%)Tj
1.9105 0 Td
(to)Tj
1.0148 0 Td
(83%\),)Tj
2.4605 0 Td
(p)Tj
0.7313 0 Td
(=)Tj
0.7937 0 Td
(0.002,)Tj
2.5398 0 Td
(over)Tj
1.9502 0 Td
(8)Tj
0.6917 0 Td
(weeks)Tj
2.5795 0 Td
(of)Tj
1.0035 0 Td
(follow-up)Tj
4.0365 0 Td
([)Tj
0.83 0.64 0.02 0 k
(19)Tj
0 g
(].)Tj
-32.0653 -1.2983 Td
(Using)Tj
2.5681 0 Td
(malaria)Tj
3.1862 0 Td
(infection)Tj
3.736 0 Td
(detected)Tj
3.5206 0 Td
(by)Tj
1.1679 0 Td
(PCR)Tj
2.0466 0 Td
(as)Tj
1.0034 0 Td
(an)Tj
1.1906 0 Td
(endpoint)Tj
3.8097 0 Td
(for)Tj
1.372 0 Td
(efficacy,)Tj
3.3902 0 Td
(we)Tj
1.3153 0 Td
(assessed)Tj
3.4242 0 Td
(the)Tj
1.4513 0 Td
(safety,)Tj
-34.3783 -1.2983 Td
(immunogenicity)Tj
6.7747 0 Td
(and)Tj
1.7121 0 Td
(efficacy)Tj
3.1748 0 Td
(of)Tj
0.9978 0 Td
(priming)Tj
3.4356 0 Td
(with)Tj
1.9729 0 Td
(the)Tj
1.4513 0 Td
(same)Tj
2.2394 0 Td
(vaccines)Tj
3.5036 0 Td
(and)Tj
1.7121 0 Td
(doses,)Tj
2.5908 0 Td
(ChAd63)Tj
3.5376 0 Td
(ME-TRAP)Tj
-33.1027 -1.3039 Td
(\(5)Tj
1.0204 0 Td
(x)Tj
0.6803 0 Td
(10)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 226.4314 646.8661 cm
BT
/F7 1 Tf
1 TL
-0.0133 Tc
0 0 Td
(5)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 232.1007 642.3874 cm
BT
/F7 1 Tf
1 TL
-0.01 Tc
0 0 Td
(vp\))Tj
1.5136 0 Td
(vaccine)Tj
3.1578 0 Td
(and)Tj
1.7121 0 Td
(boosting)Tj
3.6284 0 Td
(with)Tj
1.9785 0 Td
(MVA)Tj
2.4718 0 Td
(ME-TRAP)Tj
4.4674 0 Td
(\(2)Tj
1.0205 0 Td
(x)Tj
0.6803 0 Td
(10)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 447.8173 646.8661 cm
BT
/F7 1 Tf
1 TL
-0.0133 Tc
0 0 Td
(8)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 453.4866 642.3874 cm
BT
/F7 1 Tf
1 TL
-0.01 Tc
0 0 Td
(pfu\),)Tj
2.0919 0 Td
(8)Tj
0.686 0 Td
(weeks)Tj
2.5795 0 Td
(apart)Tj
2.245 0 Td
(in)Tj
1.0262 0 Td
(healthy)Tj
-33.9758 -1.2982 Td
(adult)Tj
2.2224 0 Td
(volunteers)Tj
4.3199 0 Td
(in)Tj
1.0262 0 Td
(Senegal.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 600.7181 cm
BT
/F3 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Methods)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 583.7102 cm
BT
/F16 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Registration:)Tj
/F7 1 Tf
5.6182 0 Td
(Pan)Tj
1.7631 0 Td
(African)Tj
3.2372 0 Td
(Clinical)Tj
3.3165 0 Td
(Trial)Tj
2.1486 0 Td
(Registry)Tj
3.481 0 Td
(\(Ref:)Tj
2.1203 0 Td
(PACTR)Tj
3.3618 0 Td
(201-303-000-499-409\);)Tj
0.83 0.64 0.02 0 k
9.3203 0 Td
(http://)Tj
-34.367 -1.2982 Td
(www.pactr.org)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 541.9842 cm
BT
/F0 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Study)Tj
2.7543 0 Td
(setting)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 524.9763 cm
BT
/F7 1 Tf
1 TL
-0.014 Tc
0 0 Td
(The)Tj
1.7517 0 Td
(study)Tj
2.3415 0 Td
(was)Tj
1.6667 0 Td
(conducted)Tj
4.337 0 Td
(in)Tj
1.0148 0 Td
(the)Tj
1.44 0 Td
(peri-urban)Tj
4.439 0 Td
(area)Tj
1.8425 0 Td
(of)Tj
0.9978 0 Td
(Dakar)Tj
2.6419 0 Td
(in)Tj
1.0148 0 Td
(Senegal,)Tj
3.3789 0 Td
(West)Tj
2.2336 0 Td
(Africa,)Tj
2.8403 0 Td
(in)Tj
1.0148 0 Td
(one)Tj
1.6725 0 Td
(of)Tj
0.9921 0 Td
(the)Tj
-35.6199 -1.2982 Td
(Universite)Tj
0 Tc
3.6566 0.051 Td
()Tj
-0.014 Tc
0.601 -0.051 Td
(Cheikh)Tj
3.0557 0 Td
(Anta)Tj
2.1373 0 Td
(Diop's)Tj
2.7496 0 Td
(\(UCAD\))Tj
3.651 0 Td
(sites)Tj
1.8708 0 Td
(located)Tj
2.9991 0 Td
(in)Tj
1.0034 0 Td
(the)Tj
1.4287 0 Td
(Roi)Tj
1.576 0 Td
(Baudoin)Tj
3.532 0 Td
(Hospital)Tj
3.5263 0 Td
(in)Tj
1.0034 0 Td
(Gue)Tj
0 Tc
1.2473 0.051 Td
()Tj
-0.014 Tc
0.3911 -0.051 Td
(diawaye)Tj
-34.4293 -1.2983 Td
(from)Tj
2.1656 0 Td
(June)Tj
2.0069 0 Td
(2012)Tj
2.0863 0 Td
(to)Tj
1.0035 0 Td
(March)Tj
2.8176 0 Td
(2013.)Tj
2.3017 0 Td
(Gue)Tj
0 Tc
1.2416 0.0511 Td
()Tj
-0.014 Tc
0.3911 -0.0511 Td
(diawaye)Tj
3.3789 0 Td
(is)Tj
0.8277 0 Td
(a)Tj
0.6407 0 Td
(small)Tj
2.279 0 Td
(town)Tj
2.2167 0 Td
(situated)Tj
3.2768 0 Td
(on)Tj
1.2586 0 Td
(the)Tj
1.44 0 Td
(coastal)Tj
2.8516 0 Td
(shoreline)Tj
3.8098 0 Td
(in)Tj
-35.9941 -1.3039 Td
(the)Tj
1.4399 0 Td
(Dakar)Tj
2.6419 0 Td
(region,)Tj
2.9594 0 Td
(bordered)Tj
3.7984 0 Td
(to)Tj
1.0034 0 Td
(the)Tj
1.44 0 Td
(East)Tj
1.8425 0 Td
(and)Tj
1.7008 0 Td
(the)Tj
1.44 0 Td
(South)Tj
2.5058 0 Td
(by)Tj
1.1622 0 Td
(the)Tj
1.44 0 Td
(town)Tj
2.2167 0 Td
(of)Tj
0.9978 0 Td
(Pikine)Tj
2.7212 0 Td
(and)Tj
1.7008 0 Td
(to)Tj
1.0034 0 Td
(the)Tj
1.44 0 Td
(West)Tj
2.228 0 Td
(by)Tj
-35.6822 -1.2983 Td
(the)Tj
1.4399 0 Td
(city)Tj
1.6214 0 Td
(of)Tj
0.9978 0 Td
(Dakar,)Tj
2.8573 0 Td
(specifically)Tj
4.4504 0 Td
(by)Tj
1.1622 0 Td
(the)Tj
1.44 0 Td
(municipal)Tj
4.1782 0 Td
(district)Tj
2.9594 0 Td
(of)Tj
0.9921 0 Td
(Parcelles)Tj
3.617 0 Td
(Assainies)Tj
3.8381 0 Td
([)Tj
0.83 0.64 0.02 0 k
(20)Tj
0 g
(].)Tj
2.0296 0 Td
(It)Tj
0.839 0 Td
(is)Tj
0.8277 0 Td
(located)Tj
-33.2501 -1.2982 Td
(approximately)Tj
5.845 0 Td
(10)Tj
1.1508 0 Td
(km)Tj
1.5137 0 Td
(from)Tj
2.1713 0 Td
(the)Tj
1.4343 0 Td
(capital,)Tj
2.9877 0 Td
(and)Tj
1.7008 0 Td
(covers)Tj
2.6986 0 Td
(an)Tj
1.1849 0 Td
(area)Tj
1.8425 0 Td
(of)Tj
0.9978 0 Td
(30)Tj
1.1508 0 Td
(km)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 459.7228 464.4283 cm
BT
/F7 1 Tf
1 TL
-0.0186 Tc
0 0 Td
(2)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 463.1811 460.0062 cm
BT
/F7 1 Tf
1 TL
-0.014 Tc
0 0 Td
(.)Tj
0.4365 0 Td
(Its)Tj
1.1905 0 Td
(population)Tj
4.4901 0 Td
(is)Tj
0.8277 0 Td
(estimated)Tj
-33.2614 -1.2982 Td
(at)Tj
0.9297 0 Td
(452,168)Tj
3.2315 0 Td
(inhabitants)Tj
4.6034 0 Td
(and)Tj
1.6951 0 Td
(the)Tj
1.44 0 Td
(average)Tj
3.1578 0 Td
(annual)Tj
2.9027 0 Td
(rainfall)Tj
2.9707 0 Td
(amounts)Tj
3.651 0 Td
(to)Tj
1.0034 0 Td
(approximately)Tj
5.8449 0 Td
(600)Tj
1.6158 0 Td
(mm.)Tj
2.0579 0 Td
(Over)Tj
-35.1039 -1.3039 Td
(the)Tj
1.44 0 Td
(past)Tj
1.7914 0 Td
(few)Tj
1.5818 0 Td
(years,)Tj
2.4321 0 Td
(malaria)Tj
3.1577 0 Td
(transmission)Tj
5.2441 0 Td
(has)Tj
1.5137 0 Td
(reached)Tj
3.2768 0 Td
(record)Tj
2.7893 0 Td
(levels)Tj
2.3131 0 Td
(in)Tj
1.0147 0 Td
(all)Tj
1.1168 0 Td
(5)Tj
0.686 0 Td
(municipal)Tj
4.1839 0 Td
(districts)Tj
-32.5414 -1.2983 Td
(within)Tj
2.7496 0 Td
(the)Tj
/F13 1 Tf
1.4399 0 Td
[()-6()2()4()16()-19(\r)7(\n)6()2()22(\r)]TJ
/F7 1 Tf
(,)Tj
5.04 0 Td
(namely)Tj
3.0898 0 Td
(Me)Tj
0 Tc
0.9014 0.051 Td
()Tj
-0.014 Tc
0.3911 -0.051 Td
(dina)Tj
1.9616 0 Td
(Gounas,)Tj
3.4696 0 Td
(Whakhinane)Tj
5.2894 0 Td
(Nimzath,)Tj
3.8663 0 Td
(Golf)Tj
1.9333 0 Td
(Sud,)Tj
1.9388 0 Td
(Sam)Tj
1.9163 0 Td
(Notaire)Tj
-33.9871 -1.2983 Td
(and)Tj
1.7007 0 Td
(Ndiareme)Tj
4.1443 0 Td
(Limamoulaye.)Tj
5.7939 0 Td
(There)Tj
2.5285 0 Td
(are)Tj
1.4173 0 Td
(several)Tj
2.863 0 Td
(reasons)Tj
3.1578 0 Td
(that)Tj
1.7405 0 Td
(account)Tj
3.3107 0 Td
(for)Tj
1.355 0 Td
(the)Tj
1.4399 0 Td
(resurgence)Tj
4.4618 0 Td
(of)Tj
-33.9134 -1.3039 Td
(malaria)Tj
3.1577 0 Td
(in)Tj
1.0148 0 Td
(the)Tj
1.44 0 Td
(Dakar)Tj
2.6419 0 Td
(suburbs:)Tj
3.5263 0 Td
(\(i\))Tj
1.1395 0 Td
(a)Tj
0.6406 0 Td
(high)Tj
1.9673 0 Td
(population)Tj
4.49 0 Td
(density,)Tj
3.2485 0 Td
(\(ii\))Tj
1.3946 0 Td
(cyclic)Tj
2.398 0 Td
(flooding)Tj
3.498 0 Td
(in)Tj
1.0147 0 Td
(lowland)Tj
3.3449 0 Td
(areas)Tj
-34.9168 -1.2982 Td
(since)Tj
2.194 0 Td
(the)Tj
1.44 0 Td
(year)Tj
1.8595 0 Td
(2000,)Tj
2.3017 0 Td
(\(iii\))Tj
1.6497 0 Td
(the)Tj
1.44 0 Td
(lack)Tj
1.7802 0 Td
(of)Tj
0.9921 0 Td
(a)Tj
0.6463 0 Td
(drainage)Tj
3.6113 0 Td
(system,)Tj
3.0954 0 Td
(and)Tj
1.7008 0 Td
(\(iv\))Tj
1.5817 0 Td
(the)Tj
1.44 0 Td
(existence)Tj
3.7643 0 Td
(of)Tj
0.9921 0 Td
(several)Tj
2.863 0 Td
(wetland)Tj
-33.3521 -1.2983 Td
(areas)Tj
2.194 0 Td
(\(containment)Tj
5.5558 0 Td
(basins,)Tj
2.8517 0 Td
(marshland,)Tj
4.6204 0 Td
(etc.\))Tj
/F16 1 Tf
-0.004 Tc
-14.0257 -1.3039 Td
(Study)Tj
2.6192 0 Td
(design)Tj
2.9196 0 Td
(and)Tj
1.7915 0 Td
(interventions.)Tj
/F7 1 Tf
6.616 0 Td
(The)Tj
1.7802 0 Td
(study)Tj
2.3924 0 Td
(was)Tj
1.6951 0 Td
(reviewed)Tj
3.7984 0 Td
(and)Tj
1.7291 0 Td
(approved)Tj
3.9741 0 Td
(by)Tj
1.1792 0 Td
(the)Tj
1.474 0 Td
()Tj
/F13 1 Tf
[()-2()11()-3()2()4()]TJ
-33.165 -1.2983 Td
[()28()22(\r)7()4()11()6()11()]TJ
3.6793 0 Td
[()59()15(\r)10()18()4()14( )4()]TJ
3.9401 0 Td
[()4()11( )12()]TJ
2.0466 0 Td
[()4()]TJ
0.9411 0 Td
[()2()7()13()6()2()20()13()6()]TJ
4.1046 0 Td
[()2()]TJ
1.1395 0 Td
[()-6()16()22(\r)11()57()]TJ
/F7 1 Tf
2.7496 0 Td
(\(CNERS\))Tj
3.9685 0 Td
(of)Tj
1.0148 0 Td
(Senegal)Tj
3.237 0 Td
(as)Tj
1.0148 0 Td
(well)Tj
1.8198 0 Td
(as)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(Direction)Tj
4.456 0 Td
(de)Tj
-36.5949 -1.2983 Td
(la)Tj
0.9014 0 Td
(Pharmacie)Tj
4.4787 0 Td
(et)Tj
0.9411 0 Td
(des)Tj
1.5307 0 Td
(Me)Tj
0 Tc
0.9127 0.0511 Td
()Tj
-0.004 Tc
0.4026 -0.0511 Td
(dicaments)Tj
4.7168 0 Td
(\(DPM\),)Tj
3.3165 0 Td
(the)Tj
1.4683 0 Td
(Senegalese)Tj
4.4447 0 Td
(regulatory)Tj
4.3199 0 Td
(authority,)Tj
4.1272 0 Td
(and)Tj
1.7348 0 Td
(Oxford)Tj
-33.2954 -1.2982 Td
(Tropical)Tj
3.5943 0 Td
(Research)Tj
3.8097 0 Td
(Ethics)Tj
2.6646 0 Td
(Committee)Tj
4.7395 0 Td
(\(OXTREC\).)Tj
4.9946 0 Td
(An)Tj
1.4513 0 Td
(independent)Tj
5.2723 0 Td
(Data)Tj
2.126 0 Td
(Safety)Tj
2.5908 0 Td
(Monitoring)Tj
-31.2431 -1.3039 Td
(Board)Tj
2.6362 0 Td
(\(DSMB\))Tj
3.5886 0 Td
(provided)Tj
3.8154 0 Td
(oversight)Tj
3.8948 0 Td
(for)Tj
1.389 0 Td
(the)Tj
1.4683 0 Td
(study.)Tj
2.6135 0 Td
(An)Tj
1.4514 0 Td
(on-site)Tj
2.9763 0 Td
(Local)Tj
2.3698 0 Td
(Safety)Tj
2.5964 0 Td
(Monitor)Tj
3.6113 0 Td
(\(LSM\))Tj
2.8063 0 Td
(acted)Tj
-35.2173 -1.2983 Td
(as)Tj
1.0148 0 Td
(liaison)Tj
2.8516 0 Td
(between)Tj
3.5263 0 Td
(the)Tj
1.4683 0 Td
(site)Tj
1.5704 0 Td
(and)Tj
1.7291 0 Td
(the)Tj
1.474 0 Td
(DSMB.)Tj
3.1295 0 Td
(The)Tj
1.7801 0 Td
(study)Tj
2.3924 0 Td
(was)Tj
1.6951 0 Td
(conducted)Tj
4.4276 0 Td
(in)Tj
1.0375 0 Td
(accordance)Tj
4.7338 0 Td
(with)Tj
2.0013 0 Td
(the)Tj
-34.8318 -1.2983 Td
(Helsinki)Tj
3.5943 0 Td
(Declaration)Tj
4.9095 0 Td
(of)Tj
1.0148 0 Td
(1964)Tj
2.126 0 Td
(\(revised)Tj
3.3902 0 Td
(in)Tj
1.0318 0 Td
(1996\))Tj
2.4662 0 Td
(and)Tj
1.7291 0 Td
(in)Tj
1.0318 0 Td
(accordance)Tj
4.7395 0 Td
(with)Tj
1.9955 0 Td
(Good)Tj
2.4774 0 Td
(Clinical)Tj
3.3165 0 Td
(Practice)Tj
-33.8226 -1.3039 Td
(\(Directive)Tj
4.2236 0 Td
(2001/83/EC,)Tj
5.193 0 Td
(amended)Tj
3.9231 0 Td
(2003/63/EC\).)Tj
5.5332 0 Td
(The)Tj
1.7802 0 Td
(University)Tj
4.405 0 Td
(of)Tj
1.0148 0 Td
(Oxford)Tj
3.1236 0 Td
(acted)Tj
2.3301 0 Td
(as)Tj
1.0148 0 Td
(study)Tj
2.3867 0 Td
(spon-)Tj
-34.9281 -1.2982 Td
(sor.)Tj
1.6837 0 Td
(The)Tj
1.7802 0 Td
(trial)Tj
1.8368 0 Td
(was)Tj
1.7008 0 Td
(registered)Tj
4.1499 0 Td
(at)Tj
0.9524 0 Td
(the)Tj
1.474 0 Td
(Pan-African)Tj
5.125 0 Td
(Clinical)Tj
3.3166 0 Td
(Trial)Tj
2.1486 0 Td
(Registry)Tj
3.4865 0 Td
(\(Ref)Tj
1.8935 0 Td
(No:)Tj
1.6895 0 Td
(PACTR)Tj
3.3562 0 Td
(201-)Tj
-34.5937 -1.2983 Td
(303-000-499-409\);)Tj
0.83 0.64 0.02 0 k
7.5457 0 Td
(http://www.pactr.org/)Tj
0 g
8.9631 0 Td
(and)Tj
1.7292 0 Td
(ClinicalTrials.gov)Tj
7.2623 0 Td
(\(Ref)Tj
1.8934 0 Td
(No:)Tj
1.6894 0 Td
(NCT01658696\);)Tj
0.83 0.64 0.02 0 k
-29.0831 -1.3039 Td
(http://clinicaltrials.gov)Tj
0 g
(.)Tj
1.1962 -1.2983 Td
(We)Tj
1.61 0 Td
(conducted)Tj
4.4277 0 Td
(a)Tj
0.6577 0 Td
(randomised,)Tj
5.2327 0 Td
(controlled,)Tj
4.5411 0 Td
(single-blinded)Tj
5.93 0 Td
(phase)Tj
2.4831 0 Td
(IIb)Tj
1.4059 0 Td
(efficacy)Tj
3.2258 0 Td
(trial.)Tj
2.0636 0 Td
(An)Tj
1.4514 0 Td
(inde-)Tj
-34.2252 -1.2983 Td
(pendent)Tj
3.5036 0 Td
(statistician)Tj
4.4787 0 Td
(based)Tj
2.4774 0 Td
(at)Tj
0.9525 0 Td
(the)Tj
1.4683 0 Td
(University)Tj
4.3994 0 Td
(of)Tj
1.0148 0 Td
(Oxford)Tj
3.1294 0 Td
(provided)Tj
3.8154 0 Td
(sealed)Tj
2.6361 0 Td
(randomisation)Tj
6.1115 0 Td
(enve-)Tj
-33.9871 -1.3039 Td
(lopes)Tj
2.2733 0 Td
(to)Tj
1.0262 0 Td
(the)Tj
1.4683 0 Td
(study)Tj
2.3924 0 Td
(site.)Tj
1.7915 0 Td
(Participants,)Tj
5.2271 0 Td
(fieldworker)Tj
4.8245 0 Td
(and)Tj
1.7291 0 Td
(laboratory)Tj
4.354 0 Td
(analysts)Tj
3.3561 0 Td
(were)Tj
2.1203 0 Td
(blinded)Tj
3.2712 0 Td
(to)Tj
1.0261 0 Td
(study)Tj
-34.8601 -1.2982 Td
(allocation)Tj
4.1272 0 Td
(of)Tj
1.0148 0 Td
(participants)Tj
4.9549 0 Td
(and)Tj
1.7291 0 Td
(remained)Tj
4.0365 0 Td
(blinded)Tj
3.2655 0 Td
(until)Tj
2.1033 0 Td
(after)Tj
2.0353 0 Td
(analysis)Tj
3.3221 0 Td
(was)Tj
1.7008 0 Td
(completed.)Tj
4.6261 0 Td
(The)Tj
1.7858 0 Td
(recom-)Tj
-34.7014 -1.2983 Td
(binant)Tj
2.8233 0 Td
(vectors)Tj
3.0557 0 Td
(have)Tj
2.0636 0 Td
(been)Tj
2.1203 0 Td
(previously)Tj
4.354 0 Td
(described)Tj
4.0478 0 Td
(in)Tj
1.0375 0 Td
(detail)Tj
2.4151 0 Td
([)Tj
0.83 0.64 0.02 0 k
(21)Tj
0 g
(].)Tj
2.0806 0 Td
(Eligible)Tj
3.2087 0 Td
(study)Tj
2.3924 0 Td
(participants)Tj
4.955 0 Td
(were)Tj
-34.554 -1.2983 Td
(randomised)Tj
5.0059 0 Td
(to)Tj
1.0262 0 Td
(receive)Tj
3.0047 0 Td
(either)Tj
2.5341 0 Td
(the)Tj
1.4684 0 Td
(ChAd63)Tj
3.5773 0 Td
(ME-TRAP)Tj
4.507 0 Td
(\(5x10)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 433.5874 152.4472 cm
BT
/F7 1 Tf
1 TL
-0.0053 Tc
0 0 Td
(5)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 439.3133 148.0251 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(vp\))Tj
1.5306 0 Td
(as)Tj
1.0148 0 Td
(prime)Tj
2.6192 0 Td
(vaccination,)Tj
5.0513 0 Td
(followed)Tj
-34.1458 -1.3039 Td
(eight)Tj
2.1997 0 Td
(weeks)Tj
2.6079 0 Td
(later)Tj
1.9955 0 Td
(by)Tj
1.1792 0 Td
(MVA)Tj
2.4945 0 Td
(ME-TRAP)Tj
4.5071 0 Td
(\(2x10)Tj
ET
Q
q
1 j
1 J
0 w
7.4999 0 0 6.6659 372.1889 139.4645 cm
BT
/F7 1 Tf
1 TL
-0.0053 Tc
0 0 Td
(8)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 377.9149 134.9858 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(pfu\))Tj
1.8935 0 Td
(as)Tj
1.0148 0 Td
(booster)Tj
3.1974 0 Td
(or)Tj
1.0999 0 Td
(two)Tj
1.7064 0 Td
(doses)Tj
2.3981 0 Td
(of)Tj
1.0148 0 Td
(anti-rabies)Tj
4.4844 0 Td
(vaccine)Tj
-34.5994 -1.2982 Td
(\(0.5ml\))Tj
3.1408 0 Td
(as)Tj
1.0148 0 Td
(comparator)Tj
4.9039 0 Td
(at)Tj
0.9524 0 Td
(the)Tj
1.4684 0 Td
(same)Tj
2.262 0 Td
(interval.)Tj
3.4866 0 Td
(All)Tj
1.3945 0 Td
(vaccines)Tj
3.5603 0 Td
(were)Tj
2.1203 0 Td
(administered)Tj
5.4879 0 Td
(intramuscularly.)Tj
/F16 1 Tf
-28.5957 -1.2983 Td
(Trial)Tj
2.2961 0 Td
(participants.)Tj
/F7 1 Tf
-0.014 Tc
6.1001 0 Td
(Healthy)Tj
3.2995 0 Td
(men)Tj
1.9843 0 Td
(aged)Tj
2.0295 0 Td
(1850)Tj
2.5908 0 Td
(years)Tj
2.211 0 Td
(old)Tj
1.474 0 Td
(were)Tj
2.0806 0 Td
(screened)Tj
3.6454 0 Td
(and)Tj
1.7007 0 Td
(120)Tj
1.6158 0 Td
(eligible)Tj
2.9877 0 Td
(vol-)Tj
-35.2117 -1.3039 Td
(unteers)Tj
3.1011 0 Td
(were)Tj
2.0863 0 Td
(selected)Tj
3.2655 0 Td
(to)Tj
1.0034 0 Td
(participate)Tj
4.3654 0 Td
(in)Tj
1.0148 0 Td
(this)Tj
1.6327 0 Td
(trial.)Tj
2.0012 0 Td
(Prior)Tj
2.2507 0 Td
(to)Tj
1.0034 0 Td
(the)Tj
1.44 0 Td
(commencement)Tj
6.5763 0 Td
(of)Tj
0.9978 0 Td
(the)Tj
1.44 0 Td
(study,)Tj
2.5512 0 Td
(local)Tj
-34.7298 -1.2983 Td
(community)Tj
4.7905 0 Td
(sensitisation)Tj
5.0287 0 Td
(\(collective)Tj
4.1555 0 Td
(and)Tj
1.7008 0 Td
(individual\))Tj
4.5126 0 Td
(meetings)Tj
3.7418 0 Td
(were)Tj
2.0749 0 Td
(held)Tj
1.9049 0 Td
(to)Tj
0.9978 0 Td
(introduce)Tj
4.0195 0 Td
(to)Tj
1.0034 0 Td
(members)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 224.5039 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Safety,)Tj
3.2882 0 Td
(Immunog)Tj
4.1031 0 Td
(enicity)Tj
3.0048 0 Td
(and)Tj
1.8567 0 Td
(Efficacy)Tj
3.6638 0 Td
(of)Tj
1.0418 0 Td
(ChAd63-M)Tj
4.7055 0 Td
(VA-METR)Tj
4.4504 0 Td
(AP)Tj
1.5378 0 Td
(against)Tj
/F6 1 Tf
3.3875 0 Td
(P.)Tj
1.1551 0 Td
(falcipar)Tj
3.1536 0 Td
(um)Tj
/F0 1 Tf
1.5945 0 Td
(in)Tj
0.9779 0 Td
(African)Tj
3.2811 0 Td
(Adults)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.4748 0 Td
(DOI:10.137)Tj
5.0387 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.0167)Tj
3.5434 0 Td
(951)Tj
2.6362 0 Td
(December)Tj
4.7622 0 Td
(15,)Tj
1.5874 0 Td
(2016)Tj
36.7515 0 Td
(3)Tj
0.7654 0 Td
(/)Tj
ET
endstream
endobj
65 0 obj
<>stream
endstream
endobj
66 0 obj
<>stream
endstream
endobj
67 0 obj
<>stream
endstream
endobj
68 0 obj
<>stream
endstream
endobj
69 0 obj
<>stream
BT
66.402 0 Td
(16)Tj
ET
Q
endstream
endobj
70 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 15 0 R/Annots 73 0 R/Contents 74 0 R/TrimBox[0 0 612 792]>>
endobj
72 0 obj
<>
endobj
75 0 obj
<>stream
/CIDInit/ProcSet findresource begin
12 dict begin begincmap
/CMapName/Adobe-Identity-UCS def
/CIDSystemInfo<>def
/CMapType 2 def
1 begincodespacerange
<0000>
endcodespacerange
1 beginbfchar
<010D><03B3>
endbfchar
endcmap
CMapName currentdict /CMap defineresource pop end end
endstream
endobj
76 0 obj
<>/FontDescriptor 77 0 R/DW 250/W[269[465]]>>
endobj
77 0 obj
<>
endobj
78 0 obj
<>stream
cvt f6 fpgm2Msf bglyfW headtr 6hhea1 $hmtx&O